Wall Street's Diverging Views on AbbVie: Citi Trims Target as Berenberg Sees Upside
As AbbVie navigates a pivotal year for its key drugs and pipeline, Wall Street analysts are offering mixed signals. While Citi adopts a cautious stance, Berenberg raises its price target, highlighting the contrasting perspectives on the pharmaceutical giant's future.